BSGM
Price
$6.50
Change
-$0.00 (-0.00%)
Updated
Jun 20 closing price
Capitalization
6.17M
CERS
Price
$1.34
Change
-$0.00 (-0.00%)
Updated
Jun 20 closing price
Capitalization
342.62M
39 days until earnings call
Interact to see
Advertisement

BSGM vs CERS

Header iconBSGM vs CERS Comparison
Open Charts BSGM vs CERSBanner chart's image
BioSig Technologies
Price$6.50
Change-$0.00 (-0.00%)
Volume$4.41K
Capitalization6.17M
Cerus
Price$1.34
Change-$0.00 (-0.00%)
Volume$2.31K
Capitalization342.62M
BSGM vs CERS Comparison Chart in %
Loading...
BSGM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BSGM vs. CERS commentary
Jun 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSGM is a Hold and CERS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 22, 2025
Stock price -- (BSGM: $6.50 vs. CERS: $1.34)
Brand notoriety: BSGM and CERS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BSGM: 1% vs. CERS: 0%
Market capitalization -- BSGM: $6.17M vs. CERS: $342.62M
BSGM [@Medical Specialties] is valued at $6.17M. CERS’s [@Medical Specialties] market capitalization is $342.62M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BSGM’s FA Score shows that 0 FA rating(s) are green whileCERS’s FA Score has 0 green FA rating(s).

  • BSGM’s FA Score: 0 green, 5 red.
  • CERS’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than BSGM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BSGM’s TA Score shows that 4 TA indicator(s) are bullish while CERS’s TA Score has 4 bullish TA indicator(s).

  • BSGM’s TA Score: 4 bullish, 5 bearish.
  • CERS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both BSGM and CERS are a bad buy in the short-term.

Price Growth

BSGM (@Medical Specialties) experienced а +1.72% price change this week, while CERS (@Medical Specialties) price change was +1.52% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.14%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +1.56%.

Reported Earning Dates

BSGM is expected to report earnings on May 19, 2025.

CERS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (-0.14% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than BSGM($6.17M). BSGM YTD gains are higher at: 336.242 vs. CERS (-12.987). CERS has higher annual earnings (EBITDA): -26.34M vs. BSGM (-28.99M). CERS has more cash in the bank: 65.9M vs. BSGM (491K). BSGM has less debt than CERS: BSGM (532K) vs CERS (96M). CERS has higher revenues than BSGM: CERS (156M) vs BSGM (141K).
BSGMCERSBSGM / CERS
Capitalization6.17M343M2%
EBITDA-28.99M-26.34M110%
Gain YTD336.242-12.987-2,589%
P/E RatioN/AN/A-
Revenue141K156M0%
Total Cash491K65.9M1%
Total Debt532K96M1%
FUNDAMENTALS RATINGS
BSGM vs CERS: Fundamental Ratings
BSGM
CERS
OUTLOOK RATING
1..100
8989
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3461
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is somewhat better than the same rating for BSGM (79). This means that CERS’s stock grew somewhat faster than BSGM’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BSGM (100). This means that CERS’s stock grew similarly to BSGM’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as BSGM (100). This means that CERS’s stock grew similarly to BSGM’s over the last 12 months.

BSGM's Price Growth Rating (34) in the Medical Specialties industry is in the same range as CERS (61). This means that BSGM’s stock grew similarly to CERS’s over the last 12 months.

BSGM's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as CERS (100). This means that BSGM’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BSGMCERS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 10 days ago
87%
Bullish Trend 19 days ago
76%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
BSGM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BON1.500.13
+9.49%
Bon Natural Life Limited
DNUT2.67N/A
N/A
Krispy Kreme
CX6.78-0.08
-1.17%
Cemex SAB de CV
MOV15.06-0.32
-2.08%
Movado Group
IKT1.66-0.04
-2.35%
Inhibikase Therapeutics

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
N/A
LAB - CERS
53%
Loosely correlated
-3.67%
NNOX - CERS
47%
Loosely correlated
-1.19%
SGHT - CERS
46%
Loosely correlated
-4.92%
BFLY - CERS
46%
Loosely correlated
-3.70%
UTMD - CERS
46%
Loosely correlated
-0.09%
More